Bone Accrual During Puberty Suppression and Gender-Affirming Therapy in Transgender Adolescents
Daniele Tienforti, Lorenzo Marinelli, Giovanni Terrana, Riccardo Di Geronimo, Luca Spagnolo, Jeroen Vervalcke, Silvia Ciancia, Marco Giorgio Baroni, Arcangelo Barbonetti, Guy T’SjoenImportance
Puberty is a critical window for bone mass acquisition, determining lifelong fracture risk. Gonadotropin-releasing hormone agonist (GnRHa)–based pubertal suppression followed by gender-affirming hormone therapy (GAHT) is increasingly used in transgender and gender-diverse (TGD) adolescents, raising concerns about peak bone mass.
Objectives
To quantify changes in bone mineral density (BMD), bone mineral apparent density (BMAD), and
Data Sources
PubMed, Scopus, Web of Science, and Cochrane Library, from inception through September 2025.
Study Selection
Longitudinal cohorts assessing BMD, BMAD, or
Data Extraction and Synthesis
Data were extracted in duplicate; study quality was assessed using the Newcastle-Ottawa Scale. Random-effects models pooled mean changes across baseline (time 0 [T0]), after GnRHa (T1), and after GAHT (T2), stratified by skeletal site and sex assigned at birth. Metaregressions examined body mass index, age, Tanner stage, and treatment duration.
Main Outcomes and Measures
Dual-energy x-ray absorptiometry–derived BMD, BMAD, and
Results
Ten cohorts comprising 751 adolescents (427 assigned female at birth [AFAB]; 324 assigned male at birth [AMAB]) were included. Lumbar spine
Conclusions and Relevance
This systematic review and meta-analysis found that pubertal suppression followed by GAHT was associated with transient